Business Description
Centessa Pharmaceuticals PLC
ISIN : US1523091007
Share Class Description:
FRA:260: ADRDescription
Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include 1) SerpinPC for Hemophilia A, B, 2) LB101 for Solid Tumors, 3) ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders, 4) MGX292 Pulmonary Arterial Hypertension (PAH) and 5) Undisclosed for Solid Tumors.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 3.03 | |||||
| Equity-to-Asset | 0.66 | |||||
| Debt-to-Equity | 0.36 | |||||
| Debt-to-EBITDA | -0.51 | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | 1.34 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -128.1 | |||||
| 3-Year EPS without NRI Growth Rate | -118.7 | |||||
| 3-Year FCF Growth Rate | -123.2 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 27.73 | |||||
| 9-Day RSI | 36.36 | |||||
| 14-Day RSI | 41.48 | |||||
| 6-1 Month Momentum % | 74.19 | |||||
| 12-1 Month Momentum % | 148.85 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 8 | |||||
| Quick Ratio | 8 | |||||
| Cash Ratio | 6.51 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -4.8 | |||||
| Shareholder Yield % | -1.3 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -2499.39 | |||||
| Net Margin % | -2204.66 | |||||
| FCF Margin % | -2371.36 | |||||
| ROE % | -53.89 | |||||
| ROA % | -38.18 | |||||
| ROIC % | -326.22 | |||||
| ROC (Joel Greenblatt) % | -1529.86 | |||||
| ROCE % | -46.11 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 142.86 | |||||
| PB Ratio | 4.18 | |||||
| Price-to-Tangible-Book | 3.86 | |||||
| EV-to-EBIT | -4.53 | |||||
| EV-to-EBITDA | -4.55 | |||||
| EV-to-Revenue | 109.83 | |||||
| EV-to-FCF | -5.18 | |||||
| Price-to-Net-Current-Asset-Value | 4.78 | |||||
| Price-to-Net-Cash | 6.88 | |||||
| Earnings Yield (Greenblatt) % | -22.09 | |||||
| FCF Yield % | -17.36 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Centessa Pharmaceuticals PLC Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 6.284 | ||
| EPS (TTM) (€) | -1.449 | ||
| Beta | 0 | ||
| Volatility % | 59.03 | ||
| 14-Day RSI | 41.48 | ||
| 14-Day ATR (€) | 0.429496 | ||
| 20-Day SMA (€) | 9.7925 | ||
| 12-1 Month Momentum % | 148.85 | ||
| 52-Week Range (€) | 3.76 - 11.2 | ||
| Shares Outstanding (Mil) | 100.31 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Centessa Pharmaceuticals PLC Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Centessa Pharmaceuticals PLC Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Centessa Pharmaceuticals PLC Frequently Asked Questions
What is Centessa Pharmaceuticals PLC(FRA:260)'s stock price today?
The current price of FRA:260 is €8.80. The 52 week high of FRA:260 is €11.20 and 52 week low is €3.76.
When is next earnings date of Centessa Pharmaceuticals PLC(FRA:260)?
The next earnings date of Centessa Pharmaceuticals PLC(FRA:260) is 2024-05-10 Est..
Does Centessa Pharmaceuticals PLC(FRA:260) pay dividends? If so, how much?
Centessa Pharmaceuticals PLC(FRA:260) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers